Compare Abeona Therapeutics Inc (ABEO) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.86. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | QDTE | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $36.60 |
52-Week Low | $4.17 | $26.85 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QDTE trades at $30.42, up 1.57% with a bearish technical signal from moving averages. The ETF generates weekly dividend income with recent payments ranging from $0.12 to $0.28 per share. Technical indicators show neutral oscillators but bearish momentum with key support at $29 and resistance at $31. Recent media coverage highlights QDTE's high distribution yield strategy through 0DTE covered call options.
The outlook remains cautious given bearish technical signals, though the high-yield distribution strategy appeals to income investors. Key risks include options strategy execution and market volatility affecting premium income. Analyst sentiment appears mixed with some highlighting competitive yield advantages while others note concentration risks in large-cap growth exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
